Study identifier:D1699C00017
ClinicalTrials.gov identifier:NCT04865406
EudraCT identifier:N/A
CTIS identifier:N/A
Forxiga Tablets General Drug Use-Results Study in patients with HF
heart failure
N/A
No
-
All
1221
Observational
15 Years - n/a
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Sept 2024 by AstraZeneca
AstraZeneca
-
To capture safety when Forxiga is administered to patients with HF in clinical practice after launch.
The purpose of the study is to review the following points during use of Forxiga Tablets (hereinafter referred to as Forxiga) in the real world setting after launch. (1) ADRs which are unexpected from the precautions for use (2) Understanding of incidence of ADRs during use of Forxiga in the real world setting (3) Factors possibly having an impact on the safety
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.